MCID: MLT019
MIFTS: 76

Multiple Myeloma malady

Cancer, Neuronal, Nephrological, Bone, Blood categories

Summaries for Multiple Myeloma

Sources:
8Disease Ontology, 43NIH Rare Diseases, 34MedlinePlus, 64Wikipedia, 47OMIM, 33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MedlinePlus:34 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. these cells are part of your immune system, which helps protect the body from germs and other harmful substances. in time, myeloma cells collect in the bone marrow and in the solid parts of bones. no one knows the exact causes of multiple myeloma, but it is more common in older people and african americans. it can run in families. common symptoms may include bone pain, often in the back or ribs broken bones weakness or fatigue weight loss repeated infections frequent infections and fevers feeling very thirsty frequent urination doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. your treatment depends on how advanced the disease is and whether you have symptoms. if you have no symptoms, you may not need treatment right away. if you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards: Multiple Myeloma, also known as plasma cell myeloma, is related to amyloidosis and plasma cell leukemia. An important gene associated with Multiple Myeloma is IRF4 (interferon regulatory factor 4), and among its related pathways is Immune response Oncostatin M signaling via JAK-Stat in human cells. The drugs cyclophosphamide and thalidomide and the compounds thalidomide and baff have been mentioned in the context of this disorder. Affiliated tissues include the plasma cells in bone marrow, and related mouse phenotype homeostasis/metabolism.

Disease Ontology:8 A myeloma that is located in the plasma cells in bone marrow.

NIH Rare Diseases:43 Multiple myeloma is a cancer of the plasma cells in the bone marrow. plasma cells help the body fight infection by producing proteins called antibodies. in multiple myeloma, plasma cells grow out of control in the bone marrow and form tumors in the areas of solid bone. the growth of these bone tumors makes it harder for the bone marrow to make healthy blood cells and platelets. this disease may also harm other tissues and organs, such as the kidneys. multiple myeloma mainly affects older adults. although the exact cause is unknown, there are several known risk factors that can increase a person's chance of getting this disease. last updated: 7/6/2011

Wikipedia:64 Multiple myeloma (from Greek myelo-, marrow), also known as plasma cell myeloma or Kahler\'s disease... more...

Description from OMIM:47 254500

Aliases & Classifications for Multiple Myeloma

Sources:
8Disease Ontology, 9diseasecard, 43NIH Rare Diseases, 22GTR, 47OMIM, 10DISEASES, 45Novoseek, 49Orphanet, 34MedlinePlus, 31LifeMap Discovery™, 61UMLS, 57SNOMED-CT, 40NCIt, 35MeSH, 27ICD9CM, 26ICD10 via Orphanet, 36MESH via Orphanet, 58SNOMED-CT via Orphanet, 62UMLS via Orphanet, 25ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer
Anatomical: Neuronal, Nephrological, Bone, Blood


Characteristics (Orphanet epidemiological data):

49
multiple myeloma:
Prevalence: 1-5/10000; Age of onset: Adulthood
primary amyloidosis:
Prevalence: 1-5/10000; Age of onset: Adulthood


Aliases & Descriptions:

multiple myeloma 8 9 43 47 10 49 34 31 61
plasma cell myeloma 43 45 49
primary systemic amyloidosis 49 61
medullary plasmacytoma 49 61
plasma cell dyscrasia 43 61
primary amyloidosis 49 61
myeloma - multiple 43 22
myelomatosis 43 49
systemic immunoglobulinic amyloidosis 49
immunoglobulin deposition disease 61
immunoglobulinic amyloidosis 49
systemic al amyloidosis 49
light-chain amyloidosis 49
kahler's disease 49
al amyloidosis 49
kahler disease 43


External Ids:

Disease Ontology8 DOID:9538
NCIt40 C3242
OMIM47 254500
MeSH35 D009101
ICD9CM27 203.0
ICD10 via Orphanet26 E85.0, E85.1, E85.2 E85.3, C90.0, E85.8, more
MESH via Orphanet36 D009101, C531616
SNOMED-CT via Orphanet58 109989006, 55921005, 23132008
UMLS via Orphanet62 C0026764, C0268381
ICD1025 C90.0

Related Diseases for Multiple Myeloma

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Multiple Myeloma family:

myeloma familial myeloma

Diseases related to Multiple Myeloma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 369)
idRelated DiseaseScoreTop Affiliating Genes
1amyloidosis31.2APOA1
2plasma cell leukemia31.1CCND1
3hypercalcemia30.6IL6R
4arthritis30.5IL6R
5follicular lymphoma30.1CCND1, IRF4, TNFRSF13C
6non-hodgkin lymphoma29.9IL6R, IRF4, TNFRSF17, TNFRSF13C, CCND1
7hematopoietic stem cell transplantation10.7
8extramedullary plasmacytoma10.7
9acute leukemia10.7
10smoldering myeloma10.6
11macroglobulinemia10.6
12t-cell leukemia10.5
13light chain deposition disease10.5
14cryoglobulinemia10.5
15cutis laxa10.5
16mu chain disease10.5
17acquired cutis laxa10.4
18osteonecrosis10.4
19fanconi syndrome10.4
20waldenstrom macroglobulinemia10.4
21essential thrombocythemia10.4
22hepatitis c10.3
23herpes zoster10.3
24adult syndrome10.3
25poems syndrome10.3
26amyloid neuropathy10.3
27scleredema10.3
28peripheral t-cell lymphoma10.3
29angiodysplasia10.3
30acute myeloid leukemia10.3
31stevens-johnson syndrome10.3
32thrombotic thrombocytopenic purpura10.3
33bone lymphoma10.3
34arthropathy10.3
35acute myelomonocytic leukemia10.3
36necrobiotic xanthogranuloma10.3
37hepatitis c virus10.3
38graft versus host disease10.3
39membranous glomerulonephritis10.3
40gaucher's disease10.3
41obstructive jaundice10.3
42hyperphosphatemia10.3
43proliferative glomerulonephritis10.3
44indolent myeloma10.3
45pyomyositis10.3
46mantle cell lymphoma10.3
47n syndrome10.3
48vasculitis10.3
49macroglossia10.3
50familial myeloma10.3

Graphical network of the top 20 diseases related to Multiple Myeloma:



Diseases related to multiple myeloma

Clinical Features for Multiple Myeloma

Sources:
47OMIM
See all sources

Clinical features from OMIM:

254500

Clinical synopsis from OMIM:

254500

Drugs & Therapeutics for Multiple Myeloma

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials, 31LifeMap Discovery™, 61UMLS, 41NDF-RT
See all sources

Genetic Tests for Multiple Myeloma

Sources:
22GTR
See all sources

Genetic tests related to Multiple Myeloma:

id Genetic test Affiliating Genes
1 Multiple Myeloma22

Anatomical Context for Multiple Myeloma

Sources:
31LifeMap Discovery™, 14FMA
See all sources

FMA organs/tissues related to Multiple Myeloma:

14
The plasma cells in bone marrow

LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine

Cells/anatomical compartments in embryo or adult related to Multiple Myeloma:
id TissueAnatomical CompartmentCell Relevance
1 BloodHematopoietic Bone MarrowHematopoietic Stem Cells Potential therapeutic candidate
2 BloodPeripheral BloodMature B-Cells Potential therapeutic candidate, affected by disease

Animal Models for Multiple Myeloma or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

MGI Mouse Phenotypes related to Multiple Myeloma:

37
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537613.0NBEA, PDZK1, TNFRSF13C, APOA1, LIG4, DKK1

Publications for Multiple Myeloma

Sources:
51PubMed
See all sources

Articles related to Multiple Myeloma:

(show top 50)    (show all 2855)
idTitleAuthorsYear
1
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. (24292625)
2014
2
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. (24356630)
2014
3
Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells. (24300915)
2014
4
Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma. (23758184)
2013
5
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. (23178544)
2013
6
Serum miR-29a as a marker of multiple myeloma. (22712836)
2013
7
A pooled analysis of alcohol consumption and risk of multiple myeloma in the international multiple myeloma consortium. (23964064)
2013
8
Multiple Myeloma and Epidural Spinal Cord Compression : Case Presentation and a Spine Surgeon's Perspective. (24175035)
2013
9
Bone marrow megakaryocytes, soluble P-selectin and thrombopoietic cytokines in multiple myeloma patients. (23855381)
2013
10
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. (23860448)
2013
11
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. (22816982)
2012
12
Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma. (22760691)
2012
13
CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line. (22445357)
2012
14
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. (22139971)
2012
15
Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma. (22245948)
2012
16
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. (22072558)
2012
17
Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients]. (22040972)
2011
18
Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. (20568250)
2010
19
The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels. (20408869)
2010
20
Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. (19862826)
2009
21
Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain. (19295251)
2009
22
Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. (19144381)
2009
23
Bortezomib-induced BiP expression and apoptosis in multiple myeloma cells]. (19236758)
2009
24
Motor neuron disease associated with multiple myeloma. (18300006)
2008
25
Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. (16962948)
2006
26
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. (16940414)
2006
27
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. (15692072)
2005
28
Molecular pathogenesis and a consequent classification of multiple myeloma. (16155016)
2005
29
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. (15004512)
2004
30
Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. (15361911)
2004
31
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. (14559802)
2003
32
A polymorphism in the angiogenesis inhibitor, endostatin, in multiple myeloma. (12479859)
2003
33
C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance. (14692531)
2003
34
Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. (12815276)
2003
35
Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. (12846810)
2003
36
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. (12200385)
2002
37
Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. (11740808)
2001
38
Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. (10654010)
2000
39
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. (11006136)
2000
40
Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. (10623426)
1999
41
Expression of beta 1 integrins (very late antigens-4 and -5) on myeloma cells and clinical correlates in patients with multiple myeloma. (9513075)
1998
42
Interferon-gamma in multiple myeloma. (8535185)
1995
43
Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience. (7591683)
1995
44
Biochemical markers of multiple myeloma]. (7699895)
1995
45
Improvement of scleredema associated with IgA multiple myeloma after chemotherapy. (8565252)
1995
46
Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. (7530507)
1995
47
The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. (8845574)
1995
48
Bacterial pyomyositis in a patient with a multiple myeloma. (1458796)
1992
49
Clinicopathologic conference: Multiple malignancies: chronic lymphocytic leukemia, malignant melanoma, multiple myeloma and acute myelomonocytic leukemia. (1054212)
1975
50
Panhypopituitarism due to multiple myeloma. (5415797)
1970

Genetic Variations for Multiple Myeloma

Expression for genes affiliated with Multiple Myeloma

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Multiple Myeloma

Search GEO for disease gene expression data for Multiple Myeloma.

Pathways for genes affiliated with Multiple Myeloma

Sources:
54Reactome, 12EMD Millipore
See all sources

Pathways related to Multiple Myeloma according to GeneCards/GeneDecks:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Immune response Oncostatin M signaling via JAK-Stat in human cells
Hide members
11.0IL6R, CCND1

Compounds for genes affiliated with Multiple Myeloma

Sources:
45Novoseek, 50PharmGKB, 60Tocris Bioscience, 11DrugBank, 29IUPHAR
See all sources

Compounds related to Multiple Myeloma according to GeneCards/GeneDecks:

idCompoundScoreTop Affiliating Genes
1thalidomide45 50 60 1114.1IL6R, DKK1, CCND1
2baff2911.0TNFRSF17, TNFRSF13C
3blys4511.0TNFRSF17, TNFRSF13C
4bcma4510.7TNFRSF17, TNFRSF13C

GO Terms for genes affiliated with Multiple Myeloma

Sources:
16Gene Ontology
See all sources

Cellular components related to Multiple Myeloma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1endomembrane systemGO:01250511.2NBEA, LECT1, TNFRSF17

Biological processes related to Multiple Myeloma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1response to X-rayGO:01016511.0LIG4, CCND1

Molecular functions related to Multiple Myeloma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00551513.5WHSC1, CCND1, PDZK1, IRF4, APOA1, LIG4

Products for genes affiliated with Multiple Myeloma

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Multiple Myeloma

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet